IBSA Group, the largest privately owned pharmaceutical company in Switzerland, has established a commercial presence in the United Statesas IBSA Pharma Inc. and is planning to directly distribute Tirosint, an FDA-approved treatment for hypothyroidism that it developed and previously distributed under license to another U.S.-based drug company.*

"IBSA has been present in the U.S. market with multiple products through third-party licensing agreements for several years," said Aldo Donati, CEO of IBSA Pharma. "The decision to directly commercialize Tirosint in the United States will allow the company to maximize the commercial value of the Tirosint franchise as well as introduce other IBSA products, some currently awaiting FDA approval."

Tirosint is the first and only levothyroxine gel cap formulation available on the U.S. market. Levothyroxine is a hormone that is normally produced by the thyroid gland. Tirosint is used to treat adults and children 6 years of age and older who suffer from hypothyroidism or inadequate levels of thyroid hormone.

IBSA aims to significantly increase the commercial and clinical support for Tirosint with its own sales force, which will roll out in the coming months. Product availability and customer service support to physicians and patients will continue as usual during the transition period.

IBSA Pharma is part of IBSA Group, which is headquartered in Lugano, Switzerland. The company is a world leader in the treatment of thyroid disease and has a diversified product portfolio of prescription drugs. With products on five continents and in over 80 countries, IBSA manufactures 14 million vials of hormones, 300 million soft gel capsules and 60 million packages of finished products every year. IBSA has a commitment to scientific research and improving the health of patients.

For more information, visit www.ibsagroup.com/media.